We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
Published online by Cambridge University Press: 01 July 2009
A 68-year-old patient who suffered from gastric cancer diagnosed 8 months earlier presented with multiple peritoneal and hepatic metastasis, despite several rounds of chemo- and radiotherapy. After admission to hospital, his general condition quickly became severely compromised. He was nearly emaciated, despite being on partial parenteral feeding. Four years earlier, due to a cardiac arrhythmia that was refractory to medication, the patient had a cardiac pacemaker (CPM) implanted, regulated to go off at frequencies of below 70 beats per minute. Given the patient's terminal situation, the team started developing some doubts about the pacemaker's effects during his dying process. The patient had mentioned his intention to donate his pacemaker after his death, but had not asked for its deactivation. The specialists were not sure about the effect of the pacemaker in unnecessarily prolonging the patient's final hour. Nevertheless, they opposed deactivation, which they considered ethically uncertain. The family, who had been initially for the deactivation, decided against it. The patient's condition was progressively deteriorating, as he was falling into a state of sopor and, later, into a coma.
1. Hanson J, Callahan D. The Goals of Medicine. The Forgotten Issues in Health Care Reform. Washington DC: Georgetown University Press; 1999; Beca JP, Ortiz A, Salas S. El derecho a morir: Un debate actual. Revista Médica de Chile 2005;133:601–6.
2. Brody H. Withdrawing intensive life-sustaining treatment: Recommendations for compassionate clinical management. New England Journal of Medicine 1997;336:652–7.
3. Rhymes JA, McCullough LB, Luchi RJ, Teasdale TA. Withdrawing very low-burden interventions in chronically ill patients. JAMA 2000;283(8):1061–3; Pellegrino ED. Decisions to withdraw life sustaining treatment: A moral algorhythm. JAMA 2000;283:1065–7.
4. Asenjo R, Zapata M, Aramburu I, Morris R, Cereceda M, Brugere S, et al. Resultados clínicos de la resincronización ventricular en pacientes con insuficiencia cardíaca severa. Revista Médica de Chile 2003;131:1101–10. Cleland JGF, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. New England Journal of Medicine 2005;352:1539–49.
5. Goldstein NE, Lampert R, Bradley E, Lynn J, Krumholz HM. Management of implantable cardioverter defibrillators in end of life care. Annals of Internal Medicine 2004;141:835–8.
6. Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hlatky MA, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhymia devices: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee on Pacemaker Implantation). Journal of the American College of Cardiology 2002;40:1703–19. Hayes DL, Lloyd MA, Friedman PA. Cardiac pacing and defibrillator: A clinical approach. New York: Futura Publishing; 2000; Asenjo R, Fajuri A, González R. Indicaciones del Implante de Marcapasos Definitivos y Desfibrilador Automático. Recomendaciones del Comité de Educación Continua de la Sociedad Chilena de Cardiología y Cirugía Cardiovascular. Revista Chilena de Cardiologia 2004;23:375–391.
7. See note 6, Hayes et al. 2000.
8. Mueller PS, Hook CC, Hayes DL. Ethical analysis of withdrawal of pacemaker or implantable cardioverter-defibrillator support at the end of life. Mayo Clinic Proceedings 2003;78:959–63; Ballantine JM. Pacemaker and defribrillator deactivation in competent hospice patients: An ethical consideration. American Journal of Hospice and Palliative Medicine 2005;22:14–9.
9. Enck RE. Management of cardiac devices as the end nears. American Journal of Hospice and Palliative Medicine 2005;22:7–8.
10. Braun TC, Hagen NA, Hartfield RE, Wyse DG. Cardiac pacemakers and implantable defibrillators in terminal care. Journal of Pain and Symptom Management 1999;18:126–31.
11. See note 8, Mueller et al. 2003 and Ballantine 2005; Reitmeier PJ, Derse AR. Retiring the pacemaker. Hastings Center Report 1997;27:24–27.
13. See note 11, Reitmeier, Derse 1997; see note 12, Berger 2005; Grassman D. EOL considerations in defibrillator deactivation. American Journal of Hospice and Palliative Medicine 2005;22:179–80; Quill T, Barold SS, Sussman BL. Discontinuing an implantable cardioverter defibrillator as a life sustaining treatment. American Journal of Cardiology 1994;74:205–7.
14. See note 8, Ballantine 2005; see note 12, Berger 2005; Meisel A, Snyder L, Quill T. Seven legal barriers to end of life care: Myth, realities, and grains of truth. JAMA 2000;284:2495–501; Silveira H. When is deactivation of artificial pacing and AICD illegal, immoral and unethical? American Journal of Geriatric Cardiology 2003;12:275–6.
15. See note 8, Ballantine 2005.
16. See note 9, Enck 2005.
18. See note 13, Grassman 2005.
19. Barry B, Henderson A. Nature of decision-making in the terminally ill patient. Cancer Nurs 1996;19(5):384–91.
20. Taboada P. El Principio de la proporcionalidad terapéutica en las decisiones de limitar tratamientos. Boletín Escuela de Medicina, Pontificia Universidad Católica de Chile 1998;27:17–23; Cabré-Pericas L, Solosna Durán JF. Limitación del esfuerzo terapéutico en medicina intensiva. Medicina Intensiva 2002;26:304–11; Barbero J, Romeo Casabona C, Gijón P, Júdez J. Limitación de esfuerzo terapéutico. Medicina Clínica 2001;117:586–94.
